Canada’s Blind Spot on Drug Safety in Pregnancy – SOGC
The Society of Obstetricians and Gynaecologists of Canada (SOGC) shared a post on LinkedIn:
“A new op-ed published in the Montreal Gazette, co-authored by SOGC CEO Dr. Diane Francoeur and SOGC member Prof. Anick Bérard, highlights a critical gap in women’s health: the lack of robust data on the safety of medications during pregnancy.
Dr. Francoeur and Prof. Bérard note that most prescription drugs approved in Canada lack adequate safety data for use in pregnancy, leaving patients and physicians to make important decisions without clear evidence.
They call for stronger national data infrastructure, sustained investment in women’s health research and better integration of real-world evidence to change behaviour and improve outcomes.
Read the full op-ed.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 29, 2026, 15:58Eric Lameignere: Can DNA Fragmentation in Cumulus Cells Predict ICSI Outcomes?
-
Oct 29, 2026, 15:50Saadat Hassan: Sperm Function Testing – Can Advanced Diagnostics Guide IVF and ICSI Selection?
-
Oct 29, 2026, 15:34Sara Spiro: Celebrating the Stories Members Have Trusted With at Maven Clinic – Here Is Mine
-
Oct 29, 2026, 15:31Dina Ibrahem: 0 Motility, 1 Critical Decision
-
Oct 29, 2026, 15:28AI and Automation in Fertility and Genomics: Pipeline or Pipe Dream? – ARCS
-
Oct 29, 2026, 15:26Michael Schindler: Large Networks or Small Centers – Who Delivers Better Care?
-
Oct 29, 2026, 15:24Denny Sakkas: Driving Innovation in Reproductive Medicine
-
Oct 29, 2026, 15:10From the President’s Gala to Booth 905 at ASRM 2026 – First Fertility
-
Oct 29, 2026, 15:04Proud to Spotlight Dr. Jannie Michielsen and the Expertise She Brings to Every Day – Sims IVF